The new formulation, which received European Commission approval in November, is the world's only liquid version of intravenous infliximab. Available in 100 mg and 350 mg vials, it eliminates the reconstitution step required for conventional freeze-dried preparations, cutting drug preparation time by about 50 percent and reducing associated labor and supply costs by about 20 percent.
Celltrion's Nordic subsidiary kicked off sales in Norway immediately after winning the national tender and will supply the product through January 2028. The company said it expects to capture about 35 percent of Norway's intravenous infliximab market through the contract.
Storage space requirements for the liquid formulation are also up to 70 percent smaller than those for the powder version, an advantage that Celltrion said resonated with European hospital procurement officials.
The rollout marks the latest step in Celltrion's drive to build what it calls a full lineup of infliximab delivery options spanning intravenous powder, intravenous liquid and subcutaneous formulations.
The company has filed patents on the liquid formulation and completed registrations in major European markets including Britain, Germany and France.
Remsima's combined IV and subcutaneous product lines held a 68 percent share of European infliximab prescriptions as of the third quarter of 2025, according to data firm IQVIA. Celltrion said it plans to extend the liquid formulation's commercial reach to France, the Netherlands and the Czech Republic later this year.
"The liquid formulation has proved its competitiveness by winning tenders immediately after launch," said Baek Seung-du, regional manager of Celltrion's Nordic affiliate.
"We will continue field-driven sales and marketing efforts to broaden prescriptions and offer better options to European patients and clinicians."
Copyright ⓒ Aju Press All rights reserved.